$ADIL

Adial Pharmaceuticals (ADIL) adjourned votes on four proposals pending Nasdaq listing approval. The company held its 2026 Annual Meeting on Sept 17, voting on some proposals but delaying others. Votes on Proposals 3–6 were adjourned to Oct 1, then further delayed to Oct 15, 2026, due to outstanding Nasdaq approval. Shareholders who submitted proxies need not act unless changing their vote.

ADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 17, 2026, Adial Pharmaceuticals, Inc. (the “Company”) convened its 2026 Annual Meeting of Stockholders (the “

ADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 ADIAL PHARMACEUTICALS, INC. UNAUDITED PRO FORMA CONDENSED FINANCIAL INFORMATION The following unaudited pro forma condensed financial information presents the historical unaudited consolidated balance sheet as of June 30, 2026 of Adial Pharmaceuticals, Inc. (“Adial”

ADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. On August 19, 2026, Adial Pharmaceuticals, Inc. (the “Company”) granted an option to purchase 307,814 shares of Company common stock to an individual as a material inducement to such person becoming an employee of the Company. Th

Adial Pharmaceuticals (ADIL) reported Q2 2026 results ended June 30, 2026, including a Q2 net loss of $52.0M ($11.25/share) versus $2.0M in Q2 2025. Cash was $28.7M. The company completed the first $32M tranche of a $64M private placement and acquired Azora Therapeutics, adding AT177 for ulcerative colitis. ADIL stock fell to $3.98.

ADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Adiel Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update Completed acquisition of Azora Therapeutics, adding AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor (“Ahr”) agonist in development for ulcerative

ADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As of August 10, 2026, Adial Pharmaceuticals, Inc. (the “Company”) anticipates that the employment of its current President

Investing.com reported U.S. insider trading for July 16, 2026. Major buys included Boundless Bio (63,969 shares, about $155.6k), ADIAL Pharmaceuticals (3,233 shares, $8,690), FIS (1,386 shares, $57.4k) and Cardiff Oncology (34,364 shares plus warrants). Major sells included Celcuity (3.1M shares, about $317.8M), Arista Networks (300k shares, about $54.2M), Butterfly Network (4.0M shares, about $29.4M), CoreWeave (307,692 shares, about $24.8M) and Venture Global (555,556 shares, about $14.3M).

Coastlands Capital LP purchased 11,753 indirectly-held shares of ADIAL PHARMACEUTICALS, INC. (ADIL) at an average of $2.78 ($2.70–$2.79) across 2 trades over 2026-07-09 to 2026-07-10.

Coastlands Capital LP purchased 25,000 indirectly-held shares of ADIAL PHARMACEUTICALS, INC. (ADIL) at $2.60 on 2026-06-29.